Antagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate.
Shan
S
Liu
Bing H
BH
Wang
Andrew R
AR
Kompa
Suree
S
Lekawanvijit
Henry
H
Krum
D000818:Animals; D002478:Cells, Cultured; D015377:Cilastatin / Q000494:pharmacology; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D007200:Indican / Q000633:toxicity; D032383:Myocytes, Cardiac / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D027362:Organic Anion Transport Protein 1 / Q000037:antagonists & inhibitors* / Q000502:physiology; D029362:Organic Anion Transporters, Sodium-Independent / Q000037:antagonists & inhibitors* / Q000502:physiology; D011339:Probenecid / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014511:Uremia / Q000139:chemically induced / Q000150:complications*; D014528:Uricosuric Agents / Q000494:pharmacology; D020257:Ventricular Remodeling / Q000187:drug effects* / Q000502:physiology
D027362:Organic Anion Transport Protein 1; D029362:Organic Anion Transporters, Sodium-Independent; D011480:Protease Inhibitors; C421043:Slc22a6 protein, rat; C421143:Slco1a5 protein, rat; D014528:Uricosuric Agents; D015377:Cilastatin; D007200:Indican; D011339:Probenecid